[HTML][HTML] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - Elsevier
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - europepmc.org
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
[PDF][PDF] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - academia.edu
abstract Aim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-
tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) …
tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) …
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus …
RD Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - eprints.soton.ac.uk
Aim: to evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre …
[PDF][PDF] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - scholar.archive.org
abstract Aim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-
tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) …
tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) …
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - ora.ox.ac.uk
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre …
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus …
R Marlow, SK Sherine Kuriyakose, N Mesaros… - 2018 - cabidigitallibrary.org
Aim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre …
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus …
R Marlow, S Kuriyakose, N Mesaros… - …, 2018 - research-information.bris.ac.uk
Aim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …